Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2 in Healthy Volunteers
Latest Information Update: 08 Apr 2022
At a glance
- Drugs NVP 1805 R1 (Primary) ; NVP 1805 R2 (Primary)
- Indications Vascular disorders
- Focus Pharmacokinetics
- Sponsors Navipharm
Most Recent Events
- 16 Dec 2020 Results published in the Advances in Therapy
- 26 Nov 2019 Status changed from recruiting to completed.
- 21 Aug 2019 Planned End Date changed from 28 Jun 2019 to 31 Dec 2019.